These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26380194)

  • 21. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Bachelot T
    Breast Cancer; 2018 Jan; 25(1):17-27. PubMed ID: 29147869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
    Bian NN; Wang YH; Min GT
    Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
    Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
    PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Deng H; Liu W; He T; Hong Z; Yi F; Wei Y; Zhang W
    Front Oncol; 2019; 9():479. PubMed ID: 31293962
    [No Abstract]   [Full Text] [Related]  

  • 25. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer.
    Kaira K; Naruse I; Imai H; Sunaga N; Hisada T; Motegi M; Asao T; Yamada M
    Chemotherapy; 2014; 60(5-6):356-9. PubMed ID: 26389778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
    Hersh EM; Del Vecchio M; Brown MP; Kefford R; Loquai C; Testori A; Bhatia S; Gutzmer R; Conry R; Haydon A; Robert C; Ernst S; Homsi J; Grob JJ; Kendra K; Agarwala SS; Li M; Clawson A; Brachmann C; Karnoub M; Elias I; Renschler MF; Hauschild A
    Ann Oncol; 2015 Nov; 26(11):2267-74. PubMed ID: 26410620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
    Bando H; Yamada Y; Tanabe S; Nishikawa K; Gotoh M; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Gastric Cancer; 2016 Jul; 19(3):919-26. PubMed ID: 26474989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
    Hotta K; Sasaki J; Saeki S; Takigawa N; Katsui K; Takayama K; Nogami N; Shioyama Y; Bessho A; Kishimoto J; Tanimoto M; Kiura K; Ichinose Y
    Clin Lung Cancer; 2016 Jan; 17(1):75-9. PubMed ID: 26387039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
    Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
    BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).
    Tanigawa N; Yamaue H; Ohyama S; Sakuramoto S; Inada T; Kodera Y; Kitagawa Y; Omura K; Terashima M; Sakata Y; Nashimoto A; Yamaguchi T; Chin K; Nomura E; Lee SW; Takeuchi M; Fujii M; Nakajima T
    Gastric Cancer; 2016 Apr; 19(2):350-360. PubMed ID: 26385385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
    Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
    J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H; Paz-Ares L; Horn L; Spigel DR; Steins M; Ready NE; Chow LQ; Vokes EE; Felip E; Holgado E; Barlesi F; Kohlhäufl M; Arrieta O; Burgio MA; Fayette J; Lena H; Poddubskaya E; Gerber DE; Gettinger SN; Rudin CM; Rizvi N; Crinò L; Blumenschein GR; Antonia SJ; Dorange C; Harbison CT; Graf Finckenstein F; Brahmer JR
    N Engl J Med; 2015 Oct; 373(17):1627-39. PubMed ID: 26412456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
    Matsuda C; Honda M; Tanaka C; Fukunaga M; Ishibashi K; Munemoto Y; Hata T; Bando H; Oshiro M; Kobayashi M; Tokunaga Y; Fujii A; Nagata N; Oba K; Mishima H
    Int J Clin Oncol; 2016 Jun; 21(3):566-72. PubMed ID: 26475356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
    Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
    Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
    Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
    BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
    Zhang Y; Hochster H; Stein S; Lacy J
    Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.